Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | exonuclease III APE | 0.002 | 0 | 0.5 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.002 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0066 | 0.2957 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.2061 | 0.697 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.002 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2957 | 0.2957 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.002 | 0 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0052 | 0.2061 | 0.697 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.002 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0177 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0052 | 0.2061 | 0.697 |
Echinococcus granulosus | tar DNA binding protein | 0.0066 | 0.2957 | 0.2957 |
Schistosoma mansoni | hypothetical protein | 0.0177 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0036 | 0.1014 | 0.3429 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2957 | 0.2957 |
Brugia malayi | RNA binding protein | 0.0066 | 0.2957 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.002 | 0 | 0.5 |
Echinococcus multilocularis | geminin | 0.0177 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0066 | 0.2957 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2957 | 0.2957 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2957 | 0.2957 |
Loa Loa (eye worm) | TAR-binding protein | 0.0066 | 0.2957 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.002 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.1014 | 0.1014 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0066 | 0.2957 | 0.2957 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.1014 | 0.3429 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0066 | 0.2957 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.002 | 0 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0052 | 0.2061 | 0.697 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.002 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0066 | 0.2957 | 0.2957 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0066 | 0.2957 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 95.2834 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.